bimagrumab + semaglutide New drugs for the treatment of obesity: do we need approaches to preserve muscle mass? | Reviews in Endocrine and Metabolic Disorders The future is coming. The

Accordingly, approved indications expanded in early 2024 to include not only reduction of hyperglycemia, but also weight management in non-diabetic patients, and even cardiovascular risk reduction in patients with elevated weight and comorbid cardiovascular disease

Cold sensitivity is not listed as a direct adverse effect in FDA prescribing information, but patients commonly report it as an indirect consequence of significant weight loss

Orfoglipron, a once-daily oral molecule, remains in successful late-stage development

By the end of 2026, core patents on semaglutide will have expired in 10 countries that represent 48 percent of the global obesity burden, according to a study published earlier this month by researchers

The pyridoxine component adds a layer to watch as well